Rochester, Minn.-based Mayo Clinic Center for Individualized Medicine has partnered with Tempus, a cancer care biotechnology company, to study personalized cancer treatment.
This partnership will benefit two studies, involving 1,000 Mayo Clinic patients. One study relates to immunotherapy in lung cancer, melanoma, bladder cancer, breast cancer and lymphoma, while the other assesses the efficacy of endocrine therapy in advanced breast cancer. Tempus will provide tumor sequencing, using machine learning and bioinformatics to generate data for the Mayo Clinic research teams.
Mayo Clinic's ultimate goal is to develop biomarkers that predict the benefit of new therapeutics for cancer treatment. During the course of the study, patients will also have access to genomic results from Tempus, which physicians may use to inform treatment decisions.